Publicaciones (47) Publicaciones de EVA DE LAGO FEMIA

2024

  1. Involvement of CB1 and CB2 receptors in neuroprotective effects of cannabinoids in experimental TDP-43 related frontotemporal dementia using male mice

    Biomedicine and Pharmacotherapy, Vol. 174

2023

  1. Preclinical investigation in FAAH inhibition as a neuroprotective therapy for frontotemporal dementia using TDP-43 transgenic male mice

    Journal of neuroinflammation, Vol. 20, Núm. 1, pp. 108

2022

  1. Discovery of Mitophagy Inhibitors with Therapeutic Potential in Different Familial Amyotrophic Lateral Sclerosis Mutations

    International Journal of Molecular Sciences, Vol. 23, Núm. 20

  2. New Statement about NRF2 in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

    Biomolecules, Vol. 12, Núm. 9

  3. TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis Therapy

    Journal of Medicinal Chemistry, Vol. 65, Núm. 2, pp. 1585-1607

2021

  1. Bip heterozigosity aggravates pathological deterioration in experimental amyotrophic lateral sclerosis

    International Journal of Molecular Sciences, Vol. 22, Núm. 22

  2. Chapter 2: Phytocannabinoids Versus Endocannabinoids. A Modern View of the Endocannabinoid System

    RSC Drug Discovery Series (Royal Society of Chemistry), pp. 10-47

  3. Inactivation of the CB2 receptor accelerated the neuropathological deterioration in TDP-43 transgenic mice, a model of amyotrophic lateral sclerosis

    Brain Pathology, Vol. 31, Núm. 6

  4. Preclinical investigation in neuroprotective effects of the gpr55 Ligand VCE-006.1 in experimental models of Parkinson’s disease and amyotrophic lateral sclerosis

    Molecules, Vol. 26, Núm. 24

  5. Recent advances in the pathogenesis and therapeutics of amyotrophic lateral sclerosis

    British Journal of Pharmacology

  6. Retinal ganglion cell loss and microglial activation in a sod1g93a mouse model of amyotrophic lateral sclerosis

    International Journal of Molecular Sciences, Vol. 22, Núm. 4, pp. 1-20

  7. Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: A new therapeutic approach for amyotrophic lateral sclerosis

    European Journal of Medicinal Chemistry, Vol. 210

  8. Targeting the CB2 receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis

    British Journal of Pharmacology, Vol. 178, Núm. 6, pp. 1373-1387

  9. Tideglusib, a non-atp competitive inhibitor of gsk-3as a drug candidate for the treatment of amyotrophic lateral sclerosis

    International Journal of Molecular Sciences, Vol. 22, Núm. 16

2020

  1. Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1δ kinase inhibitor treatment

    Scientific Reports, Vol. 10, Núm. 1

  2. Pharmacokinetics of sativex® in dogs: Towards a potential cannabinoid-based therapy for canine disorders

    Biomolecules, Vol. 10, Núm. 2

2019

  1. Targeting glial cannabinoid CB2 receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis

    British Journal of Pharmacology, Vol. 176, Núm. 10, pp. 1585-1600

2018

  1. Analysis of endocannabinoid receptors and enzymes in the post-mortem motor cortex and spinal cord of amyotrophic lateral sclerosis patients

    Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, Vol. 19, Núm. 5-6, pp. 377-386

  2. Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1G93A transgenic mice, an experimental model of amyotrophic lateral sclerosis

    Biochemical Pharmacology, Vol. 157, pp. 217-226

2017

  1. Upregulation of CB2 receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosis

    DMM Disease Models and Mechanisms, Vol. 10, Núm. 5, pp. 551-558